Login / Signup

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.

A B KimballKim A PappK ReichMelinda J GooderhamQ LiN CichanowitzC La RosaAndrew Blauvelt
Published in: The British journal of dermatology (2019)
Patients generally fared well with tildrakizumab maintenance, reinitiation, dose adjustment or initiation. What's already known about this topic? Tildrakizumab demonstrated significant efficacy vs. placebo with a positive safety profile during the first 28 weeks of treatment in two randomized double-blind trials. What does this study add? Treatment scenarios with tildrakizumab, such as long-term continuous dosing (up to 64 weeks), treatment interruption/reinitiation and switching from another biologic, can be part of the management of plaque psoriasis with a reasonable expectation of efficacy and tolerability.
Keyphrases
  • double blind
  • phase iii
  • placebo controlled
  • clinical trial
  • rheumatoid arthritis
  • randomized controlled trial
  • coronary artery disease
  • newly diagnosed
  • combination therapy
  • gestational age